Quote He would have been involved in discussions with GSK to increase the production, he has clearly developed a positive working relationship with GSK in recent years. We have seen production triple under his reign. And: Quote:Perhaps the Cook settlement wasn't that bad after all... GSK are really ramping up the drug given they have committed to a massive production increase.
LOL. Peter Cook could not have posted finer than these 2 posters!!
During the Avian Flu outbreak, GSK was forced by Government orders to increase production by more than 15 times (or greater). Using the same Cooked logic, BTA’s law suit against GSK developed a far more positive working relationship with GSK than Peter Cook’s discussions as evidenced by the more than fifteen fold production increase compared to the triple increase.
GSK's performance should be measured against market demand as reflected by orders and competitor's responses. Despite Relenza being a superior product to Tamiflu.
- $1.14 billion of the inferior Tamilu is sold for the first half year compared to $204.4 million of the superior Relenza for the full year and
- Roche is gearing up production capacity to 400 million packs compared to GSK’s 190 million courses.
This is GSK’s best effort in licensing the manufacturing : http://www.chinadaily.com.cn/bizchina/2009-02/06/content_7450505.htm
Quote: GSK reportedly licensed Chinese companies to produce Zanamivir in 2006 but it did not offer related techniques to make the drug. And The agreement grants Simcere the right to make generic copies of its influenza drug Relenza for developing countries and is intended to expand supplies of Zanamivir in areas worldwide that may be on the frontline of a possible influenza pandemic, according to GSK. "At that time, we invited the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences and Nanjing EffactPharm Drug Development Corp to join efforts to make the generic Zanamivir, because GSK provided limited technical support in synthesizing such drugs," Cao Song, a spokesman for Simcere, said.
Relenza’s production is severely inadequate and yet when Peter Cook announced the tripling of production capacity, the idiot talked it down stating the increased production will not affect BTA’s cash position and hence misled the market to question the demand for Relenza. Read this article: http://www.chinapost.com.tw/taiwan/national/national-news/2009/07/25/217661/NHI-confirms.htm
HC readers can determine for themselves the credibility of the HC posters who knew all the above facts and championed Peter Cook GSK’s pathetic performance.
BTA Price at posting:
$2.06 Sentiment: None Disclosure: Not Held
